loading
Precedente Chiudi:
$61.45
Aprire:
$61.74
Volume 24 ore:
846.49K
Relative Volume:
1.26
Capitalizzazione di mercato:
$4.29B
Reddito:
$136.86M
Utile/perdita netta:
$-168.69M
Rapporto P/E:
-22.32
EPS:
-2.81
Flusso di cassa netto:
$-113.49M
1 W Prestazione:
+1.19%
1M Prestazione:
+6.00%
6M Prestazione:
+12.84%
1 anno Prestazione:
+56.32%
Intervallo 1D:
Value
$61.00
$62.92
Intervallo di 1 settimana:
Value
$60.80
$64.00
Portata 52W:
Value
$39.46
$69.89

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name
Nome
Rhythm Pharmaceuticals Inc
Name
Telefono
857-264-4280
Name
Indirizzo
222 BERKELEY STREET, BOSTON, MA
Name
Dipendente
283
Name
Cinguettio
@rhythmpharma
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
RYTM's Discussions on Twitter

Confronta RYTM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RYTM
Rhythm Pharmaceuticals Inc
62.73 4.29B 136.86M -168.69M -113.49M -2.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-07 Aggiornamento BofA Securities Neutral → Buy
2025-03-05 Ripresa Stifel Buy
2025-01-02 Iniziato Jefferies Buy
2024-12-20 Iniziato Oppenheimer Outperform
2024-10-21 Iniziato Guggenheim Buy
2024-09-18 Iniziato H.C. Wainwright Buy
2024-09-17 Iniziato JMP Securities Mkt Outperform
2024-05-08 Downgrade BofA Securities Buy → Neutral
2023-12-19 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2023-08-01 Aggiornamento BofA Securities Neutral → Buy
2023-01-18 Ripresa Canaccord Genuity Buy
2022-08-08 Aggiornamento Goldman Neutral → Buy
2022-08-05 Aggiornamento BofA Securities Underperform → Neutral
2022-06-17 Reiterato Needham Buy
2022-03-02 Ripresa Stifel Buy
2022-02-17 Aggiornamento Ladenburg Thalmann Neutral → Buy
2021-12-08 Iniziato Wells Fargo Overweight
2021-11-19 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-09-14 Ripresa Goldman Neutral
2021-08-04 Downgrade BofA Securities Neutral → Underperform
2021-08-04 Downgrade Ladenburg Thalmann Buy → Neutral
2020-11-30 Downgrade BofA Securities Buy → Neutral
2020-01-08 Iniziato Goldman Sell
2019-07-12 Aggiornamento Stifel Hold → Buy
2019-07-08 Iniziato Canaccord Genuity Buy
2019-03-13 Iniziato Ladenburg Thalmann Buy
2018-09-07 Ripresa Morgan Stanley Overweight
2018-06-25 Reiterato Needham Buy
2018-06-15 Reiterato Needham Buy
2017-10-30 Iniziato BofA/Merrill Buy
2017-10-30 Iniziato Needham Buy
Mostra tutto

Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie

pulisher
Jun 18, 2025

GAMMA Investing LLC Grows Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Jun 18, 2025
pulisher
Jun 18, 2025

SG Americas Securities LLC Buys Shares of 19,667 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Jun 18, 2025
pulisher
Jun 18, 2025

22,192 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Assenagon Asset Management S.A. - Defense World

Jun 18, 2025
pulisher
Jun 16, 2025

(RYTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 15, 2025

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $76.62 Average Target Price from Brokerages - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Acquired by Rhumbline Advisers - Defense World

Jun 14, 2025
pulisher
Jun 09, 2025

Rhythm Pharma stock soars to all-time high of $69.7 By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Rhythm Pharmaceuticals at Goldman Sachs Conference: Strategic Focus on Rare Diseases - Investing.com Nigeria

Jun 09, 2025
pulisher
Jun 09, 2025

Rhythm Pharma stock soars to all-time high of $69.7 - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : Rhythm Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism - MSN

Jun 09, 2025
pulisher
Jun 07, 2025

Millennium Management LLC Sells 21,718 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target - Yahoo Finance

Jun 05, 2025
pulisher
Jun 05, 2025

Jefferies maintains buy rating on Rhythm Pharmaceuticals stock By Investing.com - Investing.com UK

Jun 05, 2025
pulisher
Jun 05, 2025

Citizens JMP maintains $84 target on Rhythm Pharmaceuticals stock By Investing.com - Investing.com UK

Jun 05, 2025
pulisher
Jun 04, 2025

Rhythm Pharmaceuticals at Jefferies Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
Jun 04, 2025

Rhythm Pharmaceuticals at Jefferies Conference: Strategic Pipeline Insights - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

(RYTM) Proactive Strategies - news.stocktradersdaily.com

Jun 04, 2025
pulisher
May 30, 2025

Stifel Nicolaus Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - Defense World

May 30, 2025
pulisher
May 29, 2025

Rhythm Pharmaceuticals (RYTM) Target Price Raised by Stifel Anal - GuruFocus

May 29, 2025
pulisher
May 29, 2025

12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know - Benzinga

May 29, 2025
pulisher
May 29, 2025

Rhythm Pharmaceuticals (RYTM) Stock Jumps Nearly 6%: What's Driving the Upbeat Tempo? - Daily Chhattisgarh News

May 29, 2025
pulisher
May 29, 2025

Stifel raises Rhythm Pharma stock target to $94, keeps Buy rating - Investing.com Canada

May 29, 2025
pulisher
May 29, 2025

Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | RYTM Stock News - GuruFocus

May 29, 2025
pulisher
May 28, 2025

Ameriprise Financial Inc. Purchases 11,480 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

May 28, 2025
pulisher
May 27, 2025

POMC Deficiency Obesity Market on Track for Major Expansion - openPR.com

May 27, 2025
pulisher
May 24, 2025

(RYTM) Investment Analysis - news.stocktradersdaily.com

May 24, 2025
pulisher
May 22, 2025

Deutsche Bank AG Has $2.73 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

May 22, 2025
pulisher
May 21, 2025

Gotham Asset Management LLC Sells 2,685 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

May 21, 2025
pulisher
May 21, 2025

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $75.38 Consensus Price Target from Analysts - Defense World

May 21, 2025
pulisher
May 14, 2025

Rhythm Pharmaceuticals Announces New Data Presentations on Patie - GuruFocus

May 14, 2025
pulisher
May 14, 2025

(RYTM) On The My Stocks Page - news.stocktradersdaily.com

May 14, 2025
pulisher
May 14, 2025

RYTM Shows Positive Results in Hypothalamic Obesity Treatment | - GuruFocus

May 14, 2025
pulisher
May 14, 2025

RYTM Shows Positive Results in Hypothalamic Obesity Treatment | RYTM Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

New Clinical Data: Rhythm's Obesity Drug Achieves 23% Weight Loss in Real-World Study, FDA Filing Coming Q3 - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Raymond James Financial Inc. Buys New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

May 13, 2025
pulisher
May 12, 2025

Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment - MSN

May 12, 2025
pulisher
May 12, 2025

HC Wainwright Has Negative Estimate for RYTM Q2 Earnings - Defense World

May 12, 2025
pulisher
May 09, 2025

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 6.6% on Disappointing Earnings - Defense World

May 09, 2025
pulisher
May 09, 2025

Needham & Company LLC Increases Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $72.00 - Defense World

May 09, 2025
pulisher
May 09, 2025

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 09, 2025
pulisher
May 08, 2025

Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

Rhythm Pharmaceuticals Q1 2025 slides: Revenue grows 45% as HO program advances - Investing.com Canada

May 07, 2025
pulisher
May 07, 2025

RHYTHM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

May 07, 2025
pulisher
May 07, 2025

Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga

May 07, 2025
pulisher
May 07, 2025

Rhythm Pharmaceuticals (RYTM) Price Target Raised by Needham | RYTM Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Rhythm Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat

May 07, 2025
pulisher
May 07, 2025

Earnings call transcript: Rhythm Pharmaceuticals misses Q1 2025 EPS estimates - Investing.com

May 07, 2025

Rhythm Pharmaceuticals Inc Azioni (RYTM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Rhythm Pharmaceuticals Inc Azioni (RYTM) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
German Christopher Paul
Corporate Controller & CAO
Jun 10 '25
Sale
67.19
2,069
139,016
1,889
Cramer Pamela J.
Chief Human Resources Officer
Jun 06 '25
Option Exercise
6.80
7,031
47,811
26,240
Cramer Pamela J.
Chief Human Resources Officer
Jun 06 '25
Sale
68.05
7,031
478,435
19,209
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Capitalizzazione:     |  Volume (24 ore):